|
Acute Promyelocytic Leukemia
|
0.600 |
Biomarker
|
disease |
BEFREE |
In acute promyelocytic leukemia (APL), normal retinoid signaling is disrupted by an abnormal PML-RARα fusion oncoprotein, leading to a block in cell differentiation.
|
31811682 |
2020 |
|
Acute Promyelocytic Leukemia
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
A complex translocation (1;17;15) with spliced short-type PML-RARA fusion transcripts in acute promyelocytic leukemia: A case report.
|
30680014 |
2019 |
|
Acute Promyelocytic Leukemia
|
0.600 |
Biomarker
|
disease |
BEFREE |
Moreover, arsenic targeting of normal PML also contributes to APL response in vivo.
|
30674471 |
2019 |
|
Acute Promyelocytic Leukemia
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The performances of PML-RARα detection, including admission screening, and qualitative and quantitative detection by real-time quantitative reverse transcription PCR (RT-qPCR), were assessed based on APL simulated clinical case.
|
31131502 |
2019 |
|
Acute Promyelocytic Leukemia
|
0.600 |
Biomarker
|
disease |
BEFREE |
Droplet digital PCR for quantification of PML-RARα in acute promyelocytic leukemia: a comprehensive comparison with real-time PCR.
|
30617397 |
2019 |
|
Acute Promyelocytic Leukemia
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The expression of senescence-associated beta-galactosidase (SA-β-gal), cell senescence-related markers (p16, p21, and promyelocytic leukemia; PML), and a growth marker (MCM2) was immunohistochemically examined.
|
31327484 |
2019 |
|
Acute Promyelocytic Leukemia
|
0.600 |
Biomarker
|
disease |
BEFREE |
They are also commonly deficient for expression of ATRX protein, a repressor of ALT activity, and a component of promyelocytic leukemia nuclear bodies (PML NBs) that are required for intrinsic immunity to various viruses.
|
30745338 |
2019 |
|
Acute Promyelocytic Leukemia
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
While most cases of APL harboring the PML/RARA fusion respond to all-trans retinoic acid (ATRA), some variant RARA rearrangements are ATRA insensitive.
|
31447065 |
2019 |
|
Acute Promyelocytic Leukemia
|
0.600 |
Biomarker
|
disease |
BEFREE |
Currently, more than 11 fusion partners of RARα have been identified, of which PML accounts for 95%, promyelocytic leukemia zinc finger (PLZF) take up2%, and the remaining are other variants.
|
31126665 |
2019 |
|
Acute Promyelocytic Leukemia
|
0.600 |
Biomarker
|
disease |
BEFREE |
A few cases that cannot be identified with PML-RARA by using conventional methods (karyotype analysis, FISH, and RT-PCR) involve abnormal promyelocytes that are fully in accordance with APL in morphology, cytochemistry, and immunophenotype.
|
30575821 |
2019 |
|
Acute Promyelocytic Leukemia
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
A hallmark of acute promyelocytic leukemia (APL) is the expression of PML/RARα fusion protein.
|
31592194 |
2019 |
|
Acute Promyelocytic Leukemia
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
This is the case for Acute Promyelocytic Leukemias (APL) where SUMOylation, and subsequent destruction, of the PML-RARα fusion oncoprotein are triggered by arsenic trioxide, which is used as front-line therapy in combination with retinoic acid to cure APL patients.
|
31405039 |
2019 |
|
Acute Promyelocytic Leukemia
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
In this study, we used APL cell line NB4 or P/R and PML over-expressed 293T cells as well as HeLa cells to reveal the solubility change of P/R and PML by arsenic exposure, and further determined the fate of these insoluble proteins after the removal of arsenic.
|
31670356 |
2019 |
|
Acute Promyelocytic Leukemia
|
0.600 |
Biomarker
|
disease |
BEFREE |
RARA is involved in translocation with PML in acute promyelocytic leukaemia (APL).
|
30996344 |
2019 |
|
Acute Promyelocytic Leukemia
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Acute promyelocytic leukemia (APL) is characterized by a reciprocal translocation between chromosomes 15 and 17, t(15;17), resulting in the expression of PML-RARα fusion protein, which disrupts the normal PML nuclear bodies (PML-NBs) to micro-speckled pattern, leading to loss of their original functions.
|
31669778 |
2019 |
|
Acute Promyelocytic Leukemia
|
0.600 |
Biomarker
|
disease |
BEFREE |
The hallmark reciprocal chromosomal translocation t(15;17) involving fusion between the retinoic acid receptor (RARα) gene and promyelocytic leukemia (PML) gene is a characteristic feature in APL which consequently results in the emergence of PML-RARα chimeric gene.
|
29700805 |
2019 |
|
Acute Promyelocytic Leukemia
|
0.600 |
Biomarker
|
disease |
BEFREE |
Acute promyelocytic leukemia (APL) is characterized by <i>PML-RARA</i> translocation, which causes the blockage of promyelocyte differentiation.
|
31396278 |
2019 |
|
Acute Promyelocytic Leukemia
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Our findings shed new light on the structural alterations of PML bodies and mechanisms of APL drug resistance.
|
30824184 |
2019 |
|
Acute Promyelocytic Leukemia
|
0.600 |
Biomarker
|
disease |
BEFREE |
This is the first report of an APL case presenting with submicroscopic ins(15;17) and simultaneous novel breakpoints in both PML and RARA.
|
31085908 |
2019 |
|
Acute Promyelocytic Leukemia
|
0.600 |
Biomarker
|
disease |
BEFREE |
The outcome of acute promyelocytic leukemia (APL) has drastically improved following the identification of the PML-RARA oncogene as a key player in the pathogenesis of APL, and the subsequent introduction of all-trans retinoic acid (ATRA) as a therapeutic agent.
|
30572725 |
2019 |
|
Acute Promyelocytic Leukemia
|
0.600 |
Biomarker
|
disease |
BEFREE |
In conclusion, PML IF is a fast and reliable test that facilitates accurate treatment decisions when APL is suspected.
|
30876657 |
2019 |
|
Acute Promyelocytic Leukemia
|
0.600 |
Biomarker
|
disease |
BEFREE |
Despite the rarity of APL cases with an atypical PML/RARA fusion, our study indicates that an integrated laboratory approach, employing several diagnostic techniques is crucial to timely diagnose APL.
|
30421475 |
2019 |
|
Acute Promyelocytic Leukemia
|
0.600 |
Biomarker
|
disease |
BEFREE |
However, few studies have investigated whether BRD4 influenced acute promyelocytic leukemia (APL), and whether BRD4 had interaction with promyelocytic leukemia-retinoic acid receptor α (PML/RARα) fusion protein to some extent.
|
30552662 |
2018 |
|
Acute Promyelocytic Leukemia
|
0.600 |
Biomarker
|
disease |
BEFREE |
The As2O3-mediated degradation of PML-RARA (promyelocytic leukemia-retinoic acid receptor-α) oncoprotein via the proteasome pathway appears to be critical for such distinguished sensitivity.
|
30338810 |
2018 |
|
Acute Promyelocytic Leukemia
|
0.600 |
Biomarker
|
disease |
BEFREE |
Identifying and targeting oncogenic fusion genes have revolutionized the treatment of leukemia, such as PML-RARα fusion gene in acute promyelocytic leukemia.
|
30179602 |
2018 |